Advances in preclinical evaluation of experimental antibody-drug conjugates
Tackling cisplatin resistance in ovarian cancer: what can we do?
Targeting DNA topoisomerases: past & future
Experimental models of endocrine responsive breast cancer: strengths, limitations, and use
The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors
Notch signaling in female cancers: a multifaceted node to overcome drug resistance
Targeting DNA repair pathways to overcome cancer drug resistance
MYC inhibitors in multiple myeloma
The aqueous extract of brucea javanica reduces tumorigenicity of human lung cancer tumorspheres
Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancer
Recent advances in tumor-targeting chemotherapy drugs
Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat
Erratum: P53-regulated autophagy and its impact on drug resistance and cell fate
SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance
The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma
Overview of microRNAs as liquid biopsy biomarkers for colorectal cancer sub-type profiling and chemoresistance
Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review
Barriers to achieving a cure in lymphoma
Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance
Adjuvant role of a T-type calcium channel blocker, TTA-A2, in lung cancer treatment with paclitaxel
Gene expression profiling as a prognostic tool in multiple myeloma
EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF<sup>V600E</sup> mutation: a case report and review of literature
Overcoming drug resistance by targeting protein homeostasis in multiple myeloma
Shenmai injection enhances cisplatin-induced apoptosis through regulation of Mfn2-dependent mitochondrial dynamics in lung adenocarcinoma A549/DDP cells
Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors